Modulation of the activity of sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Malek, Anastasia ^a,b   Núñez, Luz Elena ^c   Magistri, Marco ^a,b   Brambilla, Lara ^a,b   Jovic, Sandra ^a,b   Carbone, Giuseppina M ^a,b   Morís, Francisco ^c   Catapano, Carlo V ^a,b  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c Campus El Cristo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITHRAMYCIN A; MITHRAMYCIN SDK; MITHRAMYCIN SK; TRANSCRIPTION FACTOR SP; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MITHRAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SYNTHESIS; DRUG TOLERABILITY; GENE CONTROL; GENETIC ENGINEERING; HUMAN; IN VITRO STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; SUBCUTANEOUS TISSUE TUMOR; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PLICAMYCIN; PROSTATE; PROSTATIC NEOPLASMS; SP TRANSCRIPTION FACTORS;

EID: 84859868832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035130     Document Type: Article

References (49)

1. Darnell JE Jr, (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749.
2. Frank DA, (2009) Targeting transcription factors for cancer therapy. IDrugs 12: 29-33.
3. Safe S, Abdelrahim M, (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448.
4. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, et al. (2005) Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 65: 1007-1017.
5. Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, et al. (2000) Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 60: 6531-6536.
6. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, et al. (2007) Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 67: 3286-3294.
7. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S, (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67: 2816-2823.
8. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S, (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98: 855-868.
9. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R 3rd, et al. (2008) Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 68: 5345-5354.
10. Jutooru I, Chadalapaka G, Lei P, Safe S, (2010) Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 285: 25332-25344.
11. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, et al. (2010) Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol 78: 226-236.
12. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S, (2007) The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 67: 11001-11011.
13. Abdelrahim M, Samudio I, Smith R 3rd, Burghardt R, Safe S, (2002) Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 277: 28815-28822.
14. Lombo F, Menendez N, Salas JA, Mendez C, (2006) The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol 73: 1-14.
15. Miller DM, Polansky DA, Thomas SD, Ray R, Campbell VW, et al. (1987) Mithramycin selectively inhibits transcription of G-C containing DNA. Am J Med Sci 294: 388-394.
16. Sastry M, Patel DJ, (1993) Solution structure of the mithramycin dimer-DNA complex. Biochemistry 32: 6588-6604.
17. Barcelo F, Scotta C, Ortiz-Lombardia M, Mendez C, Salas JA, et al. (2007) Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res 35: 2215-2226.
18. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, et al. (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613-1621.
19. Snyder RC, Ray R, Blume S, Miller DM, (1991) Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry 30: 4290-4297.
20. Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, et al. (2003) Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry 42: 8313-8324.
21. Jia Z, Zhang J, Wei D, Wang L, Yuan P, et al. (2007) Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 67: 4878-4885.
22. Calabresi P, (1991) Antineoplastic agents, In The pharmacological basis of therapeutics. Pergamon Press, Oxford, UK.
23. Remsing LL, Garcia-Bernardo J, Gonzalez A, Kunzel E, Rix U, et al. (2002) Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway. J Am Chem Soc 124: 1606-1614.
24. Remsing LL, Gonzalez AM, Nur-e-Alam M, Fernandez-Lozano MJ, Brana AF, et al. (2003) Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc 125: 5745-5753.
25. Trefzer A, Blanco G, Remsing L, Kunzel E, Rix U, et al. (2002) Rationally designed glycosylated premithramycins: hybrid aromatic polyketides using genes from three different biosynthetic pathways. J Am Chem Soc 124: 6056-6062.
26. Perez M, Baig I, Brana AF, Salas JA, Rohr J, et al. (2008) Generation of new derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosynthesis. Chembiochem 9: 2295-2304.
27. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, et al. (2006) Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res 34: 1721-1734.
28. Gibson M, Nur-e-alam M, Lipata F, Oliveira MA, Rohr J, (2005) Characterization of kinetics and products of the Baeyer-Villiger oxygenase MtmOIV, the key enzyme of the biosynthetic pathway toward the natural product anticancer drug mithramycin from Streptomyces argillaceus. J Am Chem Soc 127: 17594-17595.
29. Previdi S, Malek A, Albertini V, Riva C, Capella C, et al. (2010) Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 118: 182-188.
30. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin.
31. Nelson WG, De Marzo AM, Isaacs WB, (2003) Prostate cancer. N Engl J Med 349: 366-381.
32. Shen MM, Abate-Shen C, (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24: 1967-2000.
33. Chun JY, Hu Y, Pinder E, Wu J, Li F, et al. (2007) Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 6: 2572-2580.
34. Jia Z, Gao Y, Wang L, Li Q, Zhang J, et al. (2010) Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res 70: 1111-1119.
35. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, et al. (2009) Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 284: 2203-2213.
36. Husbeck B, Bhattacharyya RS, Feldman D, Knox SJ, (2006) Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 5: 2078-2085.
37. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, et al. (2008) Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol 75: 2112-2121.
38. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, et al. (2009) Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30: 1193-1201.
39. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, et al. (2010) ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 5: e10547.
40. Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, et al. (2006) Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851-861.
41. Napoli S, Pastori C, Magistri M, Carbone GM, Catapano CV, (2009) Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells. EMBO J 28: 1708-1719.
42. Malek A, Catapano CV, Czubayko F, Aigner A, (2010) A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models. Clin Exp Metastasis 27: 261-271.
43. Barcelo F, Ortiz-Lombardia M, Martorell M, Oliver M, Mendez C, et al. (2010) DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 49: 10543-10552.
44. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
45. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, et al. (2011) Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 71: 5182-5193.
46. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
47. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110.
48. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, et al. (2010) A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18: 220-230.
49. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, et al. (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103: 962-978.